In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer
BMC Cancer Open Access 10 December 2021
-
lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling
Molecular Cancer Open Access 15 January 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thomas, A., Liu, S. V., Subramaniam, D. S. & Giaccone, G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12, 511–526 (2015).
Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Ramalingam, S. et al. Osimertinib versus standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol. 28 (Suppl. 5), v605–v649 (2017).
Heigener, D. F. & Reck, M. Crizotinib. Recent Results Cancer Res. 201, 197–205 (2014).
Tang, S. C. et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer 134, 1484–1494 (2014).
Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Hida, T. et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390, 29–39 (2017).
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1709937 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.F.H. and M.R. are advisory board members for, and have received honoraria for speaking and reimbursement for travel from Astra Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Pfizer, and Roche. Both authors have also received honoraria for speaking from Chugai and Fresenius; D.F.H. is an advisory board member for both companies, and M.R. for Chugai.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Heigener, D., Reck, M. Giant steps and stumbling blocks. Nat Rev Clin Oncol 15, 71–72 (2018). https://doi.org/10.1038/nrclinonc.2017.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.178
This article is cited by
-
Hedgehog ligand and receptor cooperatively regulate EGFR stability and activity in non-small cell lung cancer
Cellular Oncology (2024)
-
Tanshinone IIA (TSIIA) represses the progression of non-small cell lung cancer by the circ_0020123/miR-1299/HMGB3 pathway
Molecular and Cellular Biochemistry (2023)
-
Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer
BMC Cancer (2021)
-
lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling
Molecular Cancer (2020)